457 related articles for article (PubMed ID: 33082194)
21. Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.
Preziosa P; Storelli L; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
Neurotherapeutics; 2021 Apr; 18(2):878-888. PubMed ID: 33483938
[TBL] [Abstract][Full Text] [Related]
22. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
Izquierdo G; Damas F; Páramo MD; Ruiz-Peña JL; Navarro G
PLoS One; 2017; 12(4):e0176174. PubMed ID: 28453541
[TBL] [Abstract][Full Text] [Related]
23. Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis.
Grahl S; Bussas M; Wiestler B; Eichinger P; Gaser C; Kirschke J; Zimmer C; Berthele A; Hemmer B; Mühlau M
Neurotherapeutics; 2021 Oct; 18(4):2589-2597. PubMed ID: 34561843
[TBL] [Abstract][Full Text] [Related]
24. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Zhu C; Zhou Z; Roos I; Merlo D; Kalincik T; Ozakbas S; Skibina O; Kuhle J; Hodgkinson S; Boz C; Alroughani R; Lechner-Scott J; Barnett M; Izquierdo G; Prat A; Horakova D; Kubala Havrdova E; Macdonell R; Patti F; Khoury SJ; Slee M; Karabudak R; Onofrj M; Van Pesch V; Prevost J; Monif M; Jokubaitis V; van der Walt A; Butzkueven H;
J Neurol Neurosurg Psychiatry; 2022 Dec; 93(12):1330-1337. PubMed ID: 36261289
[TBL] [Abstract][Full Text] [Related]
25. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Spelman T; Herring WL; Zhang Y; Tempest M; Pearson I; Freudensprung U; Acosta C; Dort T; Hyde R; Havrdova E; Horakova D; Trojano M; De Luca G; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Alroughani R; Pucci E; Granella F; Lechner-Scott J; Sola P; Ferraro D; Grand'Maison F; Terzi M; Rozsa C; Boz C; Hupperts R; Van Pesch V; Oreja-Guevara C; van der Walt A; Jokubaitis VG; Kalincik T; Butzkueven H;
Pharmacoeconomics; 2022 Mar; 40(3):323-339. PubMed ID: 34921350
[TBL] [Abstract][Full Text] [Related]
26. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
Mankinen P; Lundström T; Soini E; Sumelahti ML; Ruutiainen J; Niskala U; Järvinen E
Adv Ther; 2020 Feb; 37(2):800-818. PubMed ID: 31873868
[TBL] [Abstract][Full Text] [Related]
27. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M
Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749
[TBL] [Abstract][Full Text] [Related]
28. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R
J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242
[TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.
Rollot F; Couturier J; Casey R; Wiertlewski S; Debouverie M; Pelletier J; De Sèze J; Labauge P; Ruet A; Thouvenot E; Ciron J; Berger E; Gout O; Clavelou P; Stankoff B; Casez O; Bourre B; Zephir H; Moreau T; Lebrun-Frenay C; Maillart E; Edan G; Neau JP; Montcuquet A; Cabre P; Camdessanché JP; Defer G; Nasr HB; Maurousset A; Hankiewicz K; Pottier C; Leray E; Vukusic S; Laplaud DA
Neurotherapeutics; 2022 Mar; 19(2):476-490. PubMed ID: 35217934
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
[TBL] [Abstract][Full Text] [Related]
31. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
32. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.
Andersen JB; Sharmin S; Lefort M; Koch-Henriksen N; Sellebjerg F; Sørensen PS; Hilt Christensen CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Eichau S; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Shaygannejad V; Prevost J; Skibina O; Solaro C; Karabudak R; Wijmeersch BV; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; Sèze JD; Maillart E; Zephir H; Labauge P; Defer G; Lebrun C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Marousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Leray E; Laplaud DA; Butzkueven H; Kalincik T; Vukusic S; Magyari M
Mult Scler Relat Disord; 2021 Aug; 53():103012. PubMed ID: 34116480
[TBL] [Abstract][Full Text] [Related]
33. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
[TBL] [Abstract][Full Text] [Related]
34. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
Kalincik T; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Lechner-Scott J; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Solaro C; Grand'Maison F; Hupperts R; Prevost J; Sola P; Ferraro D; Terzi M; Butler E; Slee M; Kermode A; Fabis-Pedrini M; McCombe P; Barnett M; Shaw C; Hodgkinson S; Butzkueven H;
Mult Scler; 2018 Oct; 24(12):1617-1626. PubMed ID: 28857680
[TBL] [Abstract][Full Text] [Related]
35. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
36. Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG
Arnold DL; Banwell B; Bar-Or A; Ghezzi A; Greenberg BM; Waubant E; Giovannoni G; Wolinsky JS; Gärtner J; Rostásy K; Krupp L; Tardieu M; Brück W; Stites TE; Pearce GL; Häring DA; Merschhemke M; Chitnis T;
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):483-492. PubMed ID: 32132224
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
Derfuss T; Bergvall NK; Sfikas N; Tomic DL
Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423
[TBL] [Abstract][Full Text] [Related]
38. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.
Curti E; Tsantes E; Baldi E; Caniatti LM; Ferraro D; Sola P; Granella F
Mult Scler Relat Disord; 2019 Aug; 33():146-152. PubMed ID: 31200271
[TBL] [Abstract][Full Text] [Related]
39. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Luna G; Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
JAMA Neurol; 2020 Feb; 77(2):184-191. PubMed ID: 31589278
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis.
Hou J; Kim N; Cai T; Dahal K; Weiner H; Chitnis T; Cai T; Xia Z
JAMA Netw Open; 2021 Nov; 4(11):e2134627. PubMed ID: 34783826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]